The peptide exhibits consistent efficacy in models of acute and chronic injury regardless of administration route (intraperitoneal, oral, or local application), a unique characteristic distinguishing it from other growth factors that typically require localized delivery with carrier systems
Through this management of GLP-1 use, Excellus BCBS has realized cost savings, as indicated by the graph below: In 2024, there were significant advancements with GLP-1 indications
August 1, 2025: People Who Experienced Vision Loss from Trulicity May Have New Legal Options Trulicity and other GLP-1 drugs can put people at an increased risk of a serious eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), which can cause permanent blindness
While this potential blockbuster treatment presents considerable opportunities for pharma partners, there are, of course, challenges, specifically in terms of satisfying demand